Shanghai Bao Pharmaceuticals Co., Ltd. (2659) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Shanghai Bao Pharmaceuticals Co., Ltd. HK$2.64, price HK$13.11, upside -79.9%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Shanghai Bao Pharmaceuticals Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs.
Show more
Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs. Its products include KJ017, a recombinant human hyaluronidase for subcutaneous drug delivery; KJ103, a recombinant immunoglobulin G (IgG)-degrading enzyme for IgG-mediated autoimmune diseases; and SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH CTP) for assisted reproduction. The company also develops KJ101, a recombinant human chymotrypsin developed through synthetic biology that is in Phase 2 clinical trials; KJ015, a bispecific anti HER2 antibody; BJ007, a subcutaneous formulation of ceftriaxone sodium for the treatment of bacterial infections; BJ009, a first generation cephalosporin antibiotic for treating bacterial infections, including of the skin, bones, joints, reproductive organs, blood, heart valves, respiratory tract, biliary tract, and urinary tract; and SJ04, a recombinant human chorionic gonadotropin (hCG) that can be used in assisted reproductive procedures to accelerate follicle maturation and induce ovulation. These product candidates are in Phase 1 clinical trials. In addition, it is developing BJ045, a subcutaneously administered anti CD20 antibody; BJ047, a subcutaneously administered anti CD154 antibody; BJ008, a subcutaneous formulation of cefoperazone sodium"sulbactam sodium to treat bacterial infections; and BJ044, a serine protease inhibitor with broad anti inflammatory properties. These product candidates are in the preclinical stage. Further, the company licenses its intellectual property and other deliverables and provides technical services. Shanghai Bao Pharmaceuticals Co., Ltd. was founded in 2019 and is based in Shanghai, China.
Stock analysis
Shanghai Bao Pharmaceuticals Co., Ltd. (2659) currently trades at HK$13.11, while our model-based Fair Value estimate is HK$2.64, implying the stock looks roughly 396.5% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 87/100, which puts the evidence level at low.
Scenario range: HK$1.74 (bear) to HK$3.30 (bull), the price of HK$13.11 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Shanghai Bao Pharmaceuticals Co., Ltd. reported revenue of 49.2M CNY in FY2025 versus 6.9M CNY in FY2023, a compound +166.3%/yr. Reported net income was −395M CNY in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −80%, 2659 screens richer than that median.
Fair Value models
Bear HK$1.74Fair Value HK$2.64Bull HK$3.30
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
Compare Shanghai Bao Pharmaceuticals Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score43 · Above median
Fair Value upside−80% · Bottom 25%
Profitability
Return on assets−11% · Below median
Growth and dividend
Revenue growth54% · Top 25%
Balance sheet
Debt / equity0.13× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.47× · Cheapest 25%
P/S (TTM)15.26× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)94· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shanghai Bao Pharmaceuticals Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/2659
Frequently asked questions
Is Shanghai Bao Pharmaceuticals Co., Ltd. (2659) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$2.64 versus a price of HK$13.11, about −80% upside (overvalued).
What is the fair value of 2659?
Our model-based fair value for Shanghai Bao Pharmaceuticals Co., Ltd. is HK$2.64 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$13.11.
What is the quality score of 2659?
Shanghai Bao Pharmaceuticals Co., Ltd. has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Bao Pharmaceuticals Co., Ltd. (2659)?
Our model-based price target is the fair value of HK$2.64 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario HK$1.74, optimistic scenario HK$3.30. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Bao Pharmaceuticals Co., Ltd. stock forecast for 2026?
Our models put fair value at HK$2.64, about −80% upside versus a price of HK$13.11 (overvalued). Cautious scenario HK$1.74, optimistic scenario HK$3.30. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Bao Pharmaceuticals Co., Ltd. (2659)?
Shanghai Bao Pharmaceuticals Co., Ltd. reported trailing-twelve-month revenue of about 49.2M CNY (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Shanghai Bao Pharmaceuticals Co., Ltd. (2659)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Bao Pharmaceuticals Co., Ltd. it is HK$2.64 per share (as of Sep 24, 2026), against a price of HK$13.11. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Shanghai Bao Pharmaceuticals Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 2659 trades above its calculated fair value: price HK$13.11, fair value HK$2.64, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2659?
No. The price is what the market pays today (HK$13.11); the fair value is what the company's own numbers justify (HK$2.64). For Shanghai Bao Pharmaceuticals Co., Ltd. the two are HK$10.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Bao Pharmaceuticals Co., Ltd. worth?
The market values Shanghai Bao Pharmaceuticals Co., Ltd. at about HK$5.9B (market capitalisation, as of Sep 24, 2026). Per share that is HK$13.11; our models calculate a fair value of HK$2.64 per share.
What do the bullish and bearish scenarios say about 2659?
Our models span a range for Shanghai Bao Pharmaceuticals Co., Ltd.: cautious scenario HK$1.74, base HK$2.64, optimistic HK$3.30 per share (as of Sep 24, 2026, price HK$13.11). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shanghai Bao Pharmaceuticals Co., Ltd. (2659)?
Balance-sheet figures for Shanghai Bao Pharmaceuticals Co., Ltd. (as of Sep 24, 2026): return on equity −30.6%, debt of 0.13 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
Which stocks are comparable to Shanghai Bao Pharmaceuticals Co., Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Bao Pharmaceuticals Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price HK$13.11, calculated fair value HK$2.64 (−80%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2659 calculated?
We run Shanghai Bao Pharmaceuticals Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$2.64, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Shanghai Bao Pharmaceuticals Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Bao Pharmaceuticals Co., Ltd. (2659)?
The closing price on Sep 24, 2026 was HK$13.11. Our model-based fair value is HK$2.64, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Bao Pharmaceuticals Co., Ltd. right now?
The price sits above even our optimistic bull case (HK$3.30). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$1.74 to HK$3.30) leaves room in how you read the outcome.
Key figures of Shanghai Bao Pharmaceuticals Co., Ltd.
How large is the market capitalisation of Shanghai Bao Pharmaceuticals Co., Ltd. (2659)?
The market capitalisation of Shanghai Bao Pharmaceuticals Co., Ltd. is HK$5.9B (≈ $750M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the return on equity of Shanghai Bao Pharmaceuticals Co., Ltd. (2659)?
The return on equity (ROE) of Shanghai Bao Pharmaceuticals Co., Ltd. is −30.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Bao Pharmaceuticals Co., Ltd. (2659)?
On an EBIT basis the return on assets of Shanghai Bao Pharmaceuticals Co., Ltd. is −20.0% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Bao Pharmaceuticals Co., Ltd. (2659)?
The operating margin of Shanghai Bao Pharmaceuticals Co., Ltd. is −2,692% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Bao Pharmaceuticals Co., Ltd. (2659)?
Revenue at Shanghai Bao Pharmaceuticals Co., Ltd. is growing +53.5% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Shanghai Bao Pharmaceuticals Co., Ltd. (2659) generate?
The free cash flow of Shanghai Bao Pharmaceuticals Co., Ltd. is −333M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch Shanghai Bao Pharmaceuticals Co., Ltd. in the live analysis
One click puts Shanghai Bao Pharmaceuticals Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
